{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:53:58Z","timestamp":1787662438988,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11523-024-01036-1","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T07:02:08Z","timestamp":1709708528000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+\/HER2\u2212 Breast Cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"1036_CR1","unstructured":"Global Cancer Observatory. Cancer today. 2023. https:\/\/gco.iarc.fr\/. Accessed 18 Jan 2024."},{"key":"1036_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108296","volume":"239","author":"XL Liu","year":"2022","unstructured":"Liu XL, Deng JW, Yuan Y, et al. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239: 108296.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"1036_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"35","key":"1036_CR4","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959\u201377.","journal-title":"J Clin Oncol"},{"key":"1036_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines\u00ae): breast cancer (version 5.2023). 2023. https:\/\/www.nccn.org. Accessed 18 Jan 2024."},{"issue":"5 Suppl.","key":"1036_CR6","first-page":"GS1","volume":"83","author":"H Rugo","year":"2023","unstructured":"Rugo H, Bardia A, Marm\u00e9 F, et al. Sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+\/HER2- metastatic breast cancer (mBC) [abstract no. GS1-11 plus presentation]. Cancer Res. 2023;83(5 Suppl.):GS1\u201311.","journal-title":"Cancer Res"},{"key":"1036_CR7","unstructured":"Gilead Sciences Inc. TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection, for intravenous use: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov. Accessed 18 Jan 2024."},{"key":"1036_CR8","unstructured":"Gilead Sciences Inc. Trodelvy 200 mg powder for concentrate for solution for infusion: EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu. Accessed 18 Jan 2024."},{"key":"1036_CR9","unstructured":"Gilead Sciences Canada Inc. TRODELVY\u00ae sacituzumab govitecan 180 mg lyophilized powder for solution for injection, for intravenous use: Canadian prescribing information. 2023. https:\/\/www.gilead.ca. Accessed 18 Jan 2024."},{"issue":"10","key":"1036_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019\u201325.","journal-title":"Drugs"},{"issue":"12","key":"1036_CR11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709\u201318.","journal-title":"Ann Oncol"},{"issue":"10","key":"1036_CR12","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","volume":"17","author":"TM Cardillo","year":"2011","unstructured":"Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17(10):3157\u201369.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1036_CR13","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","volume":"21","author":"AN Starodub","year":"2015","unstructured":"Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870\u20138.","journal-title":"Clin Cancer Res"},{"key":"1036_CR14","unstructured":"Sathe A, Singh I, Jones A, et al. Population pharmacokinetics (popPK) of sacituzumab govitecan (SG) in patients (pts) with locally advanced or metastatic breast cancer (mBC) or other solid tumors [abstract no. PII-082]. Clin Pharmacol Ther. 2023;113(Suppl. 1):S70."},{"issue":"29","key":"1036_CR15","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, et al. Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365\u201376.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 7","key":"1036_CR16","doi-asserted-by":"publisher","first-page":"S635","DOI":"10.1016\/j.annonc.2022.07.253","volume":"33","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Marm\u00e9 F, et al. Sacituzumab govitecan (SG) efficacy in hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study [abstract no. 214MO plus presentation]. Ann Oncol. 2022;33(Suppl. 7):S635\u20136.","journal-title":"Ann Oncol"},{"issue":"16 Suppl.","key":"1036_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1200\/JCO.2023.41.16_suppl.1082","volume":"41","author":"A Bardia","year":"2023","unstructured":"Bardia A, Rugo HS, Cortes J, et al. Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+\/HER2- metastatic breast cancer (mBC): biomarker results from the phase 3 TROPiCS-02 study [abstract no. 1082 plus poster]. J Clin Oncol. 2023;41(16 Suppl.):1082.","journal-title":"J Clin Oncol"},{"issue":"10411","key":"1036_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333.","journal-title":"Lancet"},{"issue":"16 Suppl.","key":"1036_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1200\/JCO.2023.41.16_suppl.1003","volume":"41","author":"SM Tolaney","year":"2023","unstructured":"Tolaney SM, Bardia A, Marm\u00e9 F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive\/HER2-negative (HR+\/HER2-) metastatic breast cancer (mBC) [abstract no. 1003]. J Clin Oncol. 2023;41(16 Suppl.):1003.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 7","key":"1036_CR20","doi-asserted-by":"publisher","first-page":"S1258","DOI":"10.1016\/j.annonc.2022.07.1647","volume":"33","author":"H Rugo","year":"2022","unstructured":"Rugo H, Schmid P, Tolaney S, et al. Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+\/HER2- metastatic breast cancer (MBC) [abstract no. 1553O plus presentation]. Ann Oncol. 2022;33(Suppl. 7):S1258.","journal-title":"Ann Oncol"},{"key":"1036_CR21","doi-asserted-by":"crossref","unstructured":"Tolaney S, Schmid P, Bardia A, et al. Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in HR+\/HER2- metastatic breast cancer (MBC) [abstract no. P3-07-08 plus poster]. Cancer Res. 2023;83(5 Suppl.).","DOI":"10.1158\/1538-7445.SABCS22-P3-07-08"},{"issue":"1","key":"1036_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101383","volume":"8","author":"F Marm\u00e9","year":"2023","unstructured":"Marm\u00e9 F, Rugo HS, Tolaney SM, et al. Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+\/HER2\u2013 metastatic breast cancer (mBC) [abstract no. 194P]. ESMO Open. 2023;8(1): 101383.","journal-title":"ESMO Open."},{"key":"1036_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1162360","author":"DM Shi","year":"2023","unstructured":"Shi DM, Li Y, Liang XY, et al. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1162360.","journal-title":"Front Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01036-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01036-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01036-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T06:51:59Z","timestamp":1711349519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01036-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01036-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"24 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}